Search MTEX
MANNATECH INC
Nasdaq · CIK 1056358
Last close6.64
Daily change-0.35 (-5.01%)
10 Years gain-21.50%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
MTEX · STANDARD
SIC 2833 · Medicinal Chemicals & Botanical Products · Fiscal year end 1231
Fundamental
50.8Momentum
57.7Acceleration
57.7Confidence
84.0Annual Revenue19
Quarterly Revenue54
Annual CFO11
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.0 / 25
Quality8.7 / 25
Capital Efficiency20.0 / 20
Balance Sheet12.9 / 15
Shareholder Economics9.2 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 1.5318 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Key Metrics
Revenue Growth TTM-7.81%OK
Revenue CAGR 3Y-7.66%OK
Gross Margin75.67%OK
Operating Margin1.3%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y1.53%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $108.04M | $80.96M | -$426,000.00 | -$2.96M | -$4.32M | 74.94% | -0.39% | -3.99% | n/a | 1.9M |
| 2025 FY Dec 31, 2024 | $117.87M | $91.46M | $1.43M | $2.26M | $1.96M | 77.6% | 1.21% | 1.67% | n/a | 1.89M |
| 2024 FY Dec 31, 2023 | $131.96M | $102.87M | -$964,000.00 | -$2.37M | -$3.12M | 77.95% | -0.73% | -2.36% | -48.32% | 1.87M |
| 2023 FY Dec 31, 2022 | $137.21M | $104.15M | -$405,000.00 | -$2.60M | -$3.66M | 75.91% | -0.3% | -2.67% | -102.22% | 1.91M |
| 2022 FY Dec 31, 2021 | $159.76M | $125.61M | $9.05M | $10.77M | $10.12M | 78.63% | 5.66% | 6.34% | 358.15% | 2.09M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $106.41M | sum latest 4 fiscal quarters Revenue | OK | 0001437749-26-027304, 0001437749-25-034431 |
| Revenue Growth TTM | -7.81% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001437749-26-027304, 0001437749-25-034431 |
| Revenue CAGR 3Y | -7.66% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001437749-26-012430 |
| Revenue CAGR 5Y | -6.53% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001437749-26-012430 |
| Gross Profit CAGR 3Y | -8.05% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001437749-26-012430 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001437749-26-027304, 0001437749-25-034431 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 75.67% | Gross Profit / Revenue | OK | 0001437749-26-027304, 0001437749-25-034431 |
| Operating Margin | 1.3% | Operating Income / Revenue | OK | 0001437749-26-027304, 0001437749-25-034431 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001437749-26-027304 |
| Current Ratio | 1.15x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 2.19x | (Cash + Short-term Investments) / Total Debt | OK | 0001437749-26-027304 |
| Revenue per Diluted Share | $55.13 | Revenue / Diluted Shares | OK | 0001437749-26-027304, 0001437749-25-034431 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |